NICE CG 171 can be found at :http://www.nice.org.uk/nicemedia/live/14271/65143/65143.pdf
The European CHMP has recommended the addition of new contraindications to duloxetine containing products (Yentreve and Cymbalta) to state that treatment should not be initiated in patients with uncontrolled hypertension that could expose them to a potential risk of a hypertensive crisis. For Yentreve, the committee also recommended that it should not be used in patients with severe renal impairment; this contraindication is already included in the product information for Cymbalta.
European CHMP press release: Duloxetine containing products October 2006
Duloxetine is appropriate for prescribing in primary care when pelvic floor muscle training is found to be ineffective. However. prescribers should be fully aware of the contraindications and precautions in patients with mania, bipolar disorder and seizures, and in those taking antidepressant therapies. Prescribers should also be aware that there are no published data on the use of duloxetine beyond three months
MTRAC Verdict & Summary Duloxetine (Yentreve) November 2004